Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Outperform Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $35.00 price target on the stock.

A number of other research firms also recently issued reports on DMRA. HC Wainwright started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday. They set a “buy” rating and a $45.00 target price for the company. UBS Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They set a “buy” rating and a $45.00 target price for the company. Guggenheim reissued a “buy” rating and set a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price target for the company. Finally, TD Cowen assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They issued a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ DMRA opened at $20.78 on Friday. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33. The company has a 50-day moving average of $24.50 and a 200-day moving average of $25.34. The company has a market cap of $1.28 billion, a P/E ratio of -3.72 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, equities research analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.13 EPS for the current year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Large investors have recently added to or reduced their stakes in the stock. Ikarian Capital LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $6,574,000. Jain Global LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $2,774,000. Remedium Capital Partners LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $2,772,000. Boothbay Fund Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $2,204,000. Finally, Connective Capital Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at $100,000. 14.20% of the stock is owned by institutional investors and hedge funds.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.